Kazia Therapeutics Limited - American Depositary Shares (KZIA)
9.3500
-0.1900 (-1.99%)
NASDAQ · Last Trade: Jun 12th, 10:36 AM EDT
Detailed Quote
Previous Close
9.540
Open
9.000
Bid
9.110
Ask
9.350
Day's Range
8.600 - 9.750
52 Week Range
2.860 - 79.00
Volume
423,338
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,282,674
Chart
About Kazia Therapeutics Limited - American Depositary Shares (KZIA)
Kazia Therapeutics is a biotechnology company focused on developing innovative cancer therapies, particularly for difficult-to-treat brain tumors and other malignancies. The company is dedicated to advancing its promising drug candidates through clinical trials, utilizing cutting-edge research and technology to improve patient outcomes. By harnessing the potential of novel compounds, Kazia aims to address significant unmet medical needs in oncology, striving to offer new hope to patients battling various forms of cancer. Read More
Kazia on Wednesday announced positive preclinical data for its paxalisib drug in triple-negative breast cancer. The company's stock is soaring over 77% on exceptionally high and unusual trading volume.
A new wave of innovation is reshaping small-cap markets across sectors including oncology, functional energy beverages, neuromodulation, crypto treasuries, advanced connectivity, and AI fitness. The following publicly traded companies—each under $5 per share—are generating increased investor attention with transformative developments.
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
The Benzinga Stock Whisper highlights five stocks weekly that saw increased interest from readers and could have upcoming catalysts and items investors should be watching.
